IgA nephropathy in a child with X-linked agammaglobulinemia: a case report.
Case report
Hematuria
IgA nephropathy
Proteinuria
X-linked agammaglobulinemia
Journal
BMC pediatrics
ISSN: 1471-2431
Titre abrégé: BMC Pediatr
Pays: England
ID NLM: 100967804
Informations de publication
Date de publication:
30 Apr 2024
30 Apr 2024
Historique:
received:
02
11
2023
accepted:
08
04
2024
medline:
1
5
2024
pubmed:
1
5
2024
entrez:
30
4
2024
Statut:
epublish
Résumé
X-linked agammaglobulinemia (XLA) is a primary immunodeficiency disease caused by mutations in the Bruton tyrosine kinase (BTK) gene. Individuals diagnosed with XLA are at an increased risk of developing autoimmune diseases. However, renal involvement are rare in cases of XLA. In this report, we discussed a specific case involving a 6-year-old boy with XLA who experienced recurrent upper respiratory tract infections since the age of one. He presented with symptoms of hematuria and proteinuria, and renal pathology confirmed the presence of immunoglobulin (Ig) A nephropathy. Treatment comprised glucocorticoids, mycophenolate mofetil, and intermittent intravenous immunoglobulin replacement therapy. Consequently, there was a remission of proteinuria and a partial improvement in hematuria. In this study, we describe the first case of IgA nephropathy associated with XLA. This is an interesting phenotype found in XLA, and it provides valuable insights into the process of autoimmunity and the regulation of immune function in individuals with XLA. Based on our findings, we recommend the evaluation of immunoglobulin levels in patients diagnosed with IgA nephropathy.
Sections du résumé
BACKGROUND
BACKGROUND
X-linked agammaglobulinemia (XLA) is a primary immunodeficiency disease caused by mutations in the Bruton tyrosine kinase (BTK) gene. Individuals diagnosed with XLA are at an increased risk of developing autoimmune diseases. However, renal involvement are rare in cases of XLA.
CASE PRESENTATION
METHODS
In this report, we discussed a specific case involving a 6-year-old boy with XLA who experienced recurrent upper respiratory tract infections since the age of one. He presented with symptoms of hematuria and proteinuria, and renal pathology confirmed the presence of immunoglobulin (Ig) A nephropathy. Treatment comprised glucocorticoids, mycophenolate mofetil, and intermittent intravenous immunoglobulin replacement therapy. Consequently, there was a remission of proteinuria and a partial improvement in hematuria.
CONCLUSIONS
CONCLUSIONS
In this study, we describe the first case of IgA nephropathy associated with XLA. This is an interesting phenotype found in XLA, and it provides valuable insights into the process of autoimmunity and the regulation of immune function in individuals with XLA. Based on our findings, we recommend the evaluation of immunoglobulin levels in patients diagnosed with IgA nephropathy.
Identifiants
pubmed: 38689221
doi: 10.1186/s12887-024-04746-7
pii: 10.1186/s12887-024-04746-7
doi:
Substances chimiques
Immunoglobulins, Intravenous
0
Glucocorticoids
0
Mycophenolic Acid
HU9DX48N0T
Immunosuppressive Agents
0
Types de publication
Case Reports
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
291Informations de copyright
© 2024. The Author(s).
Références
El-Sayed ZA, Abramova I, Aldave JC, Al-Herz W, Bezrodnik L, Boukari R, et al. X-linked agammaglobulinemia (XLA): phenotype, diagnosis, and therapeutic challenges around the world. World Allergy Organ J. 2019;12(3):100018.
doi: 10.1016/j.waojou.2019.100018
pubmed: 30937141
pmcid: 6439403
Weber ANR, Bittner Z, Liu X, Dang T-M, Radsak MP, Brunner C. Bruton’s tyrosine kinase: an emerging key player in innate immunity. Front Immunol. 2017;8:1454.
doi: 10.3389/fimmu.2017.01454
pubmed: 29167667
pmcid: 5682317
Hernandez-Trujillo VP, Scalchunes C, Cunningham-Rundles C, Ochs HD, Bonilla FA, Paris K, et al. Autoimmunity and inflammation in X-linked agammaglobulinemia. J Clin Immunol. 2014;34(6):627–32.
doi: 10.1007/s10875-014-0056-x
pubmed: 24909997
pmcid: 4157090
Rivas-Larrauri F, Aguilar-Zanela L, Castro-Oteo P, Rosales-Hernandez LA, Otero-Mendoza F, López-Herrera G, et al. Kawasaki disease and immunodeficiencies in children: case reports and literature review. Rheumatol Int. 2019;39(10):1829–38.
doi: 10.1007/s00296-019-04382-w
pubmed: 31312887
Yoshino A, Honda M, Kanegane H, Obata K, Matsukura H, Sakazume S, et al. Membranoproliferative glomerulonephritis in a patient with X-linked agammaglobulinemia. Pediatr Nephrol. 2006;21(1):36–8.
doi: 10.1007/s00467-005-2029-z
pubmed: 16550363
Endo LM, Giannobile JV, Dobbs AK, Foote JB, Szymanska E, Warnock DG, et al. Membranous glomerulopathy in an adult patient with X-linked agammaglobulinemia receiving intravenous gammaglobulin. J Investig Allergol Clin Immunol. 2011;21(5):405–9.
pubmed: 21905506
pmcid: 3667600
Lavrador V, Correia F, Sampaio R, Cândido C, Sameiro-Faria M, Marques L, et al. Membranoproliferative glomerulonephritis and X-linked agammaglobulinemia: an uncommon association. Case Rep Pediatr. 2014;2014:480947.
pubmed: 24716070
pmcid: 3971515
Lim LM, Chang JM, Wang IF, Chang WC, Hwang DY, Chen HC. Atypical X-linked agammaglobulinaemia caused by a novel BTK mutation in a selective immunoglobulin M deficiency patient. BMC Pediatr. 2013;13:150.
doi: 10.1186/1471-2431-13-150
pubmed: 24074005
pmcid: 3849551
Chear CT, Ismail IH, Chan KC, Noh LM, Kassim A, Latiff AH, et al. Clinical features and mutational analysis of X-linked agammaglobulinemia patients in Malaysia. Front Immunol. 2023;14:1252765.
doi: 10.3389/fimmu.2023.1252765
pubmed: 37809070
pmcid: 10560089
Han SP, Lin YF, Weng HY, Tsai SF, Fu LS. A novel BTK gene mutation in a child with atypical X-linked agammaglobulinemia and recurrent hemophagocytosis: a case report. Front Immunol. 2019;10:1953.
doi: 10.3389/fimmu.2019.01953
pubmed: 31481959
pmcid: 6711359
Broides A, Yang W, Conley ME. Genotype/phenotype correlations in X-linked agammaglobulinemia. Clin Immunol. 2006;118:195–200.
doi: 10.1016/j.clim.2005.10.007
pubmed: 16297664
Lafayette RA, Kelepouris E. Immunoglobulin a nephropathy: advances in understanding of pathogenesis and treatment. Am J Nephrol. 2018;47(Suppl 1):43–52.
doi: 10.1159/000481636
pubmed: 29852501
Lavrador V, Correia F, Sampaio R, Cândido C, Sameiro-Faria M, Marques L, et al. IgA nephropathy. Nat Rev Dis Primers. 2016;2:16001.
doi: 10.1038/nrdp.2016.1
Yang Lu, Liu P, Hongqiang Du, Chen R, Zhou Bo, Li Y, et al. Novel CD81 mutations in a chinese patient led to IgA nephropathy and impaired BCR signaling. J Clin Immunol. 2022;42(8):1672–84.
doi: 10.1007/s10875-022-01333-2
pubmed: 35849269
Vince N, Boutboul D, Mouillot G, Just N, Peralta M, Casanova J-L, et al. Defects in the CD19 complex predispose to glomerulonephritis, as well as IgG1 subclass deficiency. J Allergy Clin Immunol. 2011;127(2):538–541.e5415.
doi: 10.1016/j.jaci.2010.10.019
pubmed: 21159371
Liu C-H, Kang-Hsi Wu, Lin T-Y, Wei C-C, Lin C-Y, Chen X-X, et al. Wiskott-Aldrich syndrome with IgA nephropathy: a case report and literature review. Int Urol Nephrol. 2013;45(5):1495–500.
doi: 10.1007/s11255-012-0178-0
pubmed: 22547134
Ng Y-S, Wardemann H, Chelnis J, Cunningham-Rundles C, Meffre E. Bruton’s tyrosine kinase is essential for human B cell tolerance. J ExpMed. 2004;200(7):927–34.
doi: 10.1084/jem.20040920
Sugimoto K, Nishi H, Miyazawa T, Wada N, Izu A, Enya T, et al. Tubulointerstitial nephritis complicating IVIG therapy for X-linked agammaglobulinemia. BMC Nephrol. 2014;15: 109.
doi: 10.1186/1471-2369-15-109
pubmed: 25005715
pmcid: 4094640
Takeguchi M, Korematsu S, Miyahara H, Kuga S, Izumi T. IVIG-triggered tubulointerstitial nephritis in X-linked agammaglobulinemia. Pediatr Int. 2017;59(8):945–6.
doi: 10.1111/ped.13329
pubmed: 28707726
Chenfeng JIAO, Lili ZHAO, Ling JIANG, Feng XU, Zhen CHENG. X-linked agammaglobulinemia with membranoproliferative glomerulonephritis. J Nephrol Daily Transplant. 2021;30(4):394–8.
Knight AK, Cunningham-Rundles C. Inflammatory and autoimmune complications of common variable immune deficiency. Autoimmun Rev. 2006;5(2):156–9.
doi: 10.1016/j.autrev.2005.10.002
pubmed: 16431351
Kubo T, Uchida Y, Watanabe Y, Abe M, Nakamura A, Ono M, et al. Augmented TLR9-induced Btk activation in PIR-B-deficient B-1 cells provokes excessive autoantibody production and autoimmunity. J Exp Med. 2009;206:1971–82.
doi: 10.1084/jem.20082392
pubmed: 19687229
pmcid: 2737165